A practical reference on pentadecapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-24. Anything still debated is marked as such rather than presented as settled.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
== Chemical mechanism == The carbonyl group of the sugar reacts with the amino group of the amino acid, producing N-substituted glycosylamine and water The unstable glycosylamine undergoes Amadori rearrangement, forming ketosamines Several ways are known for the ketosamines to react further: Produce two water molecules and reductones Diacetyl, pyruvaldehyde, and other short-chain hydrolytic fission products can be formed. Produce brown nitrogenous polymers and melanoidins
The conservation of energy is a common feature in many physical theories. From a mathematical point of view it is understood as a consequence of Noether's theorem, developed by Emmy Noether in 1915 and first published in 1918. In any physical theory that obeys the stationary-action principle, the theorem states that every continuous symmetry has an associated conserved quantity; if the theory's symmetry is time invariance, then the conserved quantity is called "energy". The energy conservation law is a consequence of the shift symmetry of time; energy conservation is implied by the empirical fact that the laws of physics do not change with time itself. Philosophically this can be stated as "nothing depends on time per se". In other words, if the physical system is invariant under the continuous symmetry of time translation, then its energy (which is the canonical conjugate quantity to time) is conserved. Conversely, systems that are not invariant under shifts in time (e.g. systems with time-dependent potential energy) do not exhibit conservation of energy – unless we consider them to exchange energy with another, external system so that the theory of the enlarged system becomes time-invariant again. Conservation of energy for finite systems is valid in physical theories such as special relativity and quantum theory (including QED) in the flat space-time.
A later vertebrate study identified protein tyrosine phosphatase receptor F (PTPRF), a member of the LAR family, as a conserved cognate receptor for the glucogenic actions of asprosin. In zebrafish, two Ptprf paralogs (ptprfa/b) are expressed in liver, bind asprosin with nanomolar affinity, and are required for asprosin-induced hyperglycemia and upregulation of gluconeogenic genes; soluble Ptprf ligand-binding domains neutralize the glucogenic effects and lower basal glucose, while ptprfa/b knockout fish show hypoglycemia and a blunted response to asprosin but normal responses to glucagon. In mice, PTPRF is expressed in liver and binds asprosin; Ptprf-deficient animals exhibit impaired asprosin-induced glucose production and reduced hepatic G6pc and Pck1 induction, and Ptprf deletion improves glucose tolerance without altering Olfr734 expression. Mechanistically, the same study showed that asprosin promotes insulin receptor and Akt dephosphorylation via PTPRF, counteracting insulin's suppression of gluconeogenesis and suggesting that chronic asprosin–PTPRF signaling contributes to hepatic insulin resistance. Several other independent studies have confirmed asprosin's glucogenic function.
The Tijuana Cartel, also known as the Arellano Félix Organization, was once among Mexico's most powerful. It is based in Tijuana, one of the most strategically important border towns in Mexico, and continues to export drugs even after being weakened by an internal war in 2009. Due to infighting, arrests, and the deaths of some of its top members, the Tijuana Cartel is a fraction of what it was in the 1990s and early 2000s. After the arrest or assassination of various members of the Arellano Félix family, the cartel is currently allegedly headed by Edwin Huerta Nuño, alias "El Flako".
Sources: en.wikipedia.org
Clorazepate, sold under the brand name Tranxene among others, is a benzodiazepine medication. It possesses anxiolytic, anticonvulsant, sedative, hypnotic, and skeletal muscle relaxant properties. Clorazepate is an unusually long-lasting benzodiazepine and serves as a prodrug for the equally long-lasting desmethyldiazepam, which is rapidly produced as an active metabolite. Desmethyldiazepam is responsible for most of the therapeutic effects of clorazepate. It was patented in 1965 and approved for medical use in 1967.
== History == The benefit and side effects of loncastuximab tesirine were evaluated in one clinical trial, ADCT-402-201 (LOTIS-2 / NCT03589469), that included 145 participants with relapsed or refractory diffuse large B-cell lymphoma after at least two prior treatments that did not work or were no longer working. Participants received loncastuximab tesirine 0.15 mg/kg every 3 weeks for 2 treatment cycles, then 0.075 mg/kg every 3 weeks for subsequent treatment cycles. Loncastuximab tesirine treatment was continued until either disease worsened or participants experienced unacceptable side effects (toxicity). The benefit of loncastuximab tesirine was evaluated by measuring how many participants had complete or partial tumor shrinkage (response) and by how long that response lasted. Participants in the clinical trial were also evaluated for side effects for the purpose of this drug application. Trials were conducted at 28 sites in the United States, the United Kingdom, Italy, and Switzerland. Loncastuximab tesirine was granted orphan drug designation by the FDA for the treatment of diffuse large B-cell lymphoma. Loncastuximab tesirine was approved under FDA's accelerated approval program.
Canned (tinned) instant soups contain liquid soup that is prepared by heating their contents. Some canned soups are condensed, and require additional water to bring them to their intended strength, while others are canned in a ready-to-eat, single-strength form. Dr. John T. Dorrance, an employee with the Campbell Soup Company, invented condensed soup in 1897. Consumers sometimes use condensed soups (without diluting them), as a sauce base. Some instant liquid soups are manufactured in microwaveable containers. Additionally, some instant soups, such as Knorr's Erbswurst, are prepared in a concentrated paste form. Knorr ceased production of Erbswurst on December 31, 2018. Instant noodle soups such as Cup Noodles contain dried instant ramen noodles, dehydrated vegetable and meat products, and seasonings, and are prepared by adding hot water. Packaged instant ramen noodle soup is typically formed as a cake, and often includes a seasoning packet that is added to the noodles and water during preparation. Some also include separate packets of oil and garnishes used to season the product. Momofuku Ando, the founder of Nissin Foods, developed packaged ramen noodle soup in 1958.
Light-emitting diodes (LEDs) can be manufactured to emit radiation in the ultraviolet range. In 2019, following significant advances over the preceding five years, UVA LEDs of 365 nm and longer wavelength were available, with efficiencies of 50% at 1.0 W output. Currently, the most common types of UV LEDs are in 395 nm and 365 nm wavelengths, both of which are in the UVA spectrum. The rated wavelength is the peak wavelength that the LEDs put out, but both higher and lower wavelengths are present. The cheaper and more common 395 nm UV LEDs are much closer to the visible spectrum, and give off a purple color. Other UV LEDs deeper into the spectrum do not emit as much visible light. LEDs are used for applications such as UV curing applications, charging glow-in-the-dark objects such as paintings or toys, and lights for detecting counterfeit money and bodily fluids. UV LEDs are also used in digital print applications and inert UV curing environments. As technological advances beginning in the early 2000s have improved their output and efficiency, they have become increasingly viable alternatives to more traditional UV lamps for use in UV curing applications, and the development of new UV LED curing systems for higher-intensity applications is a major subject of research in the field of UV curing technology. UVC LEDs are developing rapidly, but may require testing to verify effective disinfection. Citations for large-area disinfection are for non-LED UV sources known as germicidal lamps.
=== Contestants === 1st - Lyndsy McDonald, Executive Pastry Chef from Sarasota, Florida 2nd - Michelle Honeman, Home Baker from Beaverton, Oregon 3rd - Jamal Lake, Bakery Owner from West Palm Beach, Florida 4th - Steven Vargas Jr., Pastry Cook from Houston, Texas 5th - Brenda Villacorta, Pastry Chef from New York, New York 6th - Cicely Austin, University Executive Pastry Chef from Anderson, South Carolina 7th - Andrew Fuller, Home Bakery Owner from Des Moines, Iowa 8th - Brian Fishman, Bakery Owner from Long Island, New York
Sources: en.wikipedia.org
== Applications == As the most prevalent morphology of nanomaterials used in consumer products, nanoparticles have an enormous range of potential and actual applications. Table below summarizes the most common nanoparticles used in various product types available on the global markets. Scientific research on nanoparticles is intense as they have many potential applications in pre-clinical and clinical medicine, physics, optics, and electronics. The U.S. National Nanotechnology Initiative offers government funding focused on nanoparticle research. The use of nanoparticles in laser dye-doped poly(methyl methacrylate) (PMMA) laser gain media was demonstrated in 2003 and it has been shown to improve conversion efficiencies and to decrease laser beam divergence. Researchers attribute the reduction in beam divergence to improved dn/dT characteristics of the organic-inorganic dye-doped nanocomposite. The optimum composition reported by these researchers is 30% w/w of SiO2 (~ 12 nm) in dye-doped PMMA. Nanoparticles are being investigated as a potential drug delivery system. Drugs, growth factors or other biomolecules can be conjugated to nano particles to aid targeted delivery. This nanoparticle-assisted delivery allows for spatial and temporal controls of the loaded drugs to achieve the most desirable biological outcome. Nanoparticles are also studied for possible applications as dietary supplements for delivery of biologically active substances, for example mineral elements.
Some species of fungi live most of their life cycles as molds in soil, but upon entering a host animal, they transition to a yeast form, along with expression of virulence factors that convert them into effective and dangerous pathogens. These are known as dimorphic fungi and are typically capable of reproduction in the typical yeast fashion, including via budding. In these organisms, the yeast form transition is required for pathogenicity; if the transition is stopped somehow, the mold form does not cause disease. The rounded and separated forms of yeasts help them to spread through the bloodstream to organ systems. In some infections caused by dimorphic fungi, such as emergomycosis, respiratory symptoms are uncommon, even though the fungus initially enters through the lungs. Most molds are not dimorphic, and only a very small number of species cause dimorphic fungal disease in humans.
In 2015, 251 million tubes of toothpaste were sold in the United States. A single tube holds roughly 170 grams of toothpaste, so approximately 43 kilotonnes of toothpaste get washed into the water systems annually. Toothpaste contains silver nanoparticles, also known as nanosilver or AgNPs, among other compounds. Each tube of toothpaste contains approximately 91 mg of silver nanoparticles, with approximately 3.9 tonnes of silver nanoparticles entering the environment annually. Silver nanoparticles are not entirely cleared from the water during the wastewater treatment process, possibly leading to detrimental environmental effects.
The heavy isotope plutonium-244 has a half-life long enough that extreme trace quantities should have survived primordially (from the Earth's formation) to the present, but so far experiments have not yet been sensitive enough to detect it. Both plutonium-239 and plutonium-241 are fissile, meaning they can sustain a nuclear chain reaction, leading to applications in nuclear weapons and nuclear reactors. Plutonium-240 has a high rate of spontaneous fission, raising the neutron flux of any sample containing it. The presence of plutonium-240 limits a plutonium sample's usability for weapons or its quality as reactor fuel, and the percentage of plutonium-240 determines its grade (weapons-grade, fuel-grade, or reactor-grade). Plutonium-238 has a half-life of 87.7 years and emits alpha particles. It is a heat source in radioisotope thermoelectric generators, which are used to power some spacecraft. Plutonium isotopes are expensive and inconvenient to separate, so particular isotopes are usually manufactured in specialized reactors. Producing plutonium in useful quantities for the first time was a major part of the Manhattan Project during World War II that developed the first atomic bombs. The Fat Man bombs used in the Trinity nuclear test in July 1945, and in the bombing of Nagasaki in August 1945, had plutonium cores. Human radiation experiments studying plutonium were conducted without informed consent, and several criticality accidents, some lethal, occurred after the war.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.